{'fraction_non_alphanumeric': 0.02763819095477387, 'fraction_numerical': 0.005862646566164154, 'mean_word_length': 4.7451923076923075, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Serum somatomedin activity measured as sulphation factor in peripheral, hepatic and renal veins in normal mongrel dogs: Early effects of intravenous injection of growth hormone.

The aim of this work was to study the early effects of an intravenous growth hormone (GH) injection on serum somatomedin (SM) activity in samples from peripheral (PV), hepatic (HV) and renal (RV) veins in dogs: 5 dogs were given one bovine growth hormone (bGH) injection, 1 dog was given 5 different doses of human growth hormone (hGH) and 6 control dogs were given saline. In bGH-treated dogs, a significant increase of SM activity occurred in the three vessels without difference between vessels. An early paradoxical decrease of serum somatomedin activity appeared in the dogs given more than 1.15 IU/kg. In the dog given hGH, the response of SM activity was significantly related to the hGH dose in the PV and not in the other vessels. These data seem to indicate that other sites than the liver and the kidney are involved in the production of GH-induced serum somatomedin activity. Following GH injection as well as in basal status, the liver may be implicated in the regulation of serum somatomedin activity.